TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01289639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 30 mg po qd
Study: NCT03806270

Intervention type: DRUG
Intervention: Midazolam
Description: Demizolam 15mg/ml ampules, given orally with cherry juice

Intervention type: DRUG
Intervention: Midazolam
Description: Demizolam 15mg/ml ampules, given orally with cherry juice

Intervention type: DRUG
Intervention: Hydroxyzine Dihydrochloride
Description: Atarax 2mg/ml syrup, given orally

Intervention type: DRUG
Intervention: Hydroxyzine Dihydrochloride
Description: Atarax 2mg/ml syrup, given orally
Study: NCT00911534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole sodium
Description: One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
Study: NCT03932851

Intervention type: OTHER
Intervention: IVF-ET
Description: HBV-infected pregnant women and non-HBV-infected pregnant women underwent IVF operation

Intervention type: OTHER
Intervention: IVF-ET
Description: HBV-infected pregnant women and non-HBV-infected pregnant women underwent IVF operation
Study: NCT02133534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Study: NCT03059901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caminamos App
Description: Mobile phone that encourages Latina women to walk together through social support.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Caminamos App
Description: Mobile phone that encourages Latina women to walk together through social support.
Study: NCT04913844

Intervention type: OTHER
Intervention: Physical performance tests and observational assessments
Description: There will be no interventions. Physical performance tests and observational assessments will be conducted.

Intervention type: OTHER
Intervention: Physical performance tests and observational assessments
Description: There will be no interventions. Physical performance tests and observational assessments will be conducted.
Study: NCT01289639

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 1 capsule po qd
Study: NCT00675389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Health Workers Intervention
Description: Peer health workers are themselves PLWHA on ART who have demonstrated good ART adherence for at least 6 months. The peers are responsible for \~15-20 patients and are expected to visit the patients in their homes once every two weeks. At these visits, peers record a review of symptoms, client self-report of adherence, and a pill count. At the clinic, peers assist with patient organization and share their experiences, particularly with patients about to start ART. Peer health workers undergo an initial, intensive two day residential training course and are provided with a bike and basic supplies, and a modest amount of remuneration to encourage compliance with their responsibilities and promote a high program retention rate.
Study: NCT04557241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief informational infographic
Description: The primary intervention in this study will be an infographic that is designed to build trust in the scientific process. Infographics are preferable to narratives or text because they center visuals as part of the storytelling process and facilitate cognitive information processing, knowledge absorption, and enhanced persuasion. The study's infographic design will follow best practices in health communication. The message will be simple and jargon free. Visuals will include individuals (scientists), charts, text, and numbers. Attention will be paid to images, color, frames, representation, and composition (e.g., how the elements in the infographic are organized to show their relationship to each other).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control (non-behavioral infographic)
Description: The comparator in this study will be a control (placebo) infographic that is completely unrelated to science (e.g., about cats), but that is developed using the same communication and graphical style.
Study: NCT00744965

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
Study: NCT00675389

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Health Workers and Mobile Phone Intervention
Description: In addition to the peer health worker intervention, this arm adds a mobile phone intervention consisting of the following: during home visits, peers with mobile phones, using data collected on their home visit forms, send real-time text messages containing this clinical and adherence data back to the central clinic to be reviewed by clinical staff within a 24 hour period. Peers may also call, toll-free, back to a central clinic Warmline with any questions or concerns.
Study: NCT00744965

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sham dose adjustments of the placebo will be made.
Study: NCT00983203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 114657 ORB Preserved Ocular Emulsion
Description: 1 drop OU

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soothe XP Lubricant Eye Drops
Description: 1 drop OU
Study: NCT03716609

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Citrate
Description: Pure Magnesium citrate powder 2.07 gram from NOW FOODS (Bloomingdale, IL, USA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food grade citrate acid
Description: Food grade citrate acid 0.1 gram from San Fu Chemical Co., Ltd (Taipei, Taiwan)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Food grade citrate acid
Description: Food grade citrate acid 0.1 gram from San Fu Chemical Co., Ltd (Taipei, Taiwan)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splenda(Sucralose)
Description: Splenda 1.0 gram from Splenda(Carmel, Indiana, USA)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Splenda(Sucralose)
Description: Splenda 1.0 gram from Splenda(Carmel, Indiana, USA)
Study: NCT01733108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glyburide
Description: One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin (JNJ-28431754)
Description: One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
Study: NCT02115555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIT-aided approach
Description: Subjects randomized to this approach will be using the HIT-aided monitor.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contracted conflict management system
Description: Subjects randomized to this arm will be using the behavioral contracted conflict management system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIT plus contracted conflict management
Description: Subjects randomized to this arm will use both the HIT-aided approach and the behavioral contract conflict management system.
Study: NCT04073888

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Semen collection
Description: Semen collection for seminogram and spermocytogram
Study: NCT03461952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 240mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 1mg/kg
Study: NCT04509193

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Participants receive rivaroxaban (per written prescription, medication administration or self-report of medication use)

Intervention type: DRUG
Intervention: Warfarin
Description: Participants receive warfarin (per written prescription, medication administration or self-report of medication use)
Study: NCT02860130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prismocitrate 18
Description: Modality of CVVHDF

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Anticoagulation
Description: Modality of CVVHDF
Study: NCT01359332

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moderate hypothermia
Description: procedure of moderate hypothermia therapy, between 32 ° and 34 ° C for 24 hours
Study: NCT04681820

Intervention type: DRUG
Intervention: Flumatinib
Description: Flumatinib mesylate tablets 600mg qd for 24 months

Intervention type: DRUG
Intervention: Flumatinib
Description: Flumatinib mesylate tablets 600mg qd for 24 months

Intervention type: DRUG
Intervention: Nilotinib
Description: Nilotinib Capsules 400mg bid for 24 months

Intervention type: DRUG
Intervention: Nilotinib
Description: Nilotinib Capsules 400mg bid for 24 months
Study: NCT04634591

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Bariatric surgery (Roux-en-Y gastric bypass, gastric banding, or sleeve gastrectomy) for the treatment of morbid obesity
Study: NCT02514798

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal and gastric balloons
Description: Esophageal and gastric pressures will be measured with an esophageal ballon positioned at the lower third of the esophagus, filled with 0.5 mL of air and a gastric balloon filled with 1 mL of air. The proper position of balloons will be verified using the occlusion test as previously described. Transdiaphragmatic pressure (Pdi) is calculated as the difference between gastric (Pga) and esophageal (Pes) pressure. The pressure time integrals of the diaphragm and the other inspiratory muscles are calculated per breath (PTPdi/b and PTPes/b, respectively) and per minute (PTPdi/min and PTPes/min). Measurements will be collected at baseline, at each randomized HFNC and CPAP settings during the last 4 minutes of each 10 minutes session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esophageal and gastric balloons
Description: Esophageal and gastric pressures will be measured with an esophageal ballon positioned at the lower third of the esophagus, filled with 0.5 mL of air and a gastric balloon filled with 1 mL of air. The proper position of balloons will be verified using the occlusion test as previously described. Transdiaphragmatic pressure (Pdi) is calculated as the difference between gastric (Pga) and esophageal (Pes) pressure. The pressure time integrals of the diaphragm and the other inspiratory muscles are calculated per breath (PTPdi/b and PTPes/b, respectively) and per minute (PTPdi/min and PTPes/min). Measurements will be collected at baseline, at each randomized HFNC and CPAP settings during the last 4 minutes of each 10 minutes session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Inductance Plethysmography (RIP) system
Description: Inspiratory tidal volume (VTi), respiratory rate (RR), breath duration (Ttot), inspiratory time (Ti) and fractional inspiratory time (Ti/Ttot) will be determined using a Respiratory Inductive Plethysmography (RIP) system. This will measure the thoracic and abdominal excursion of the subjects via two inductive wires which are sewn into the elastic bands that encircle the thorax and abdomen. The acquired signals represent changes in cross-sectional area and, following calibration to determine the relative contribution of each signal, and volume calibration using spirometry, their weighted sum will reflect VTi. The RIP companion software will be used to derive RR, Ttot, Ti and Ti/Ttot on a breath by breath basis.
Study: NCT03452007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Stimulation
Description: Spinal cord epidural stimulation will be administered through a multi-electrode array implanted in the epidural space over the dorsum of the spinal cord. An implanted package containing stimulating circuits, rechargeable battery, and wireless communication activates the electrodes (16 platinum electrodes arranged in three columns of \[5-6-5\]). The pattern of electrically active electrodes, as well as electrode voltage, stimulating frequency, and stimulating pulse width will be varied to facilitate effects toward bladder function.
Study: NCT01887938

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HGT-1110
Description: Participants will receive IT injection of HGT-1110.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HGT-1110
Description: Participants will receive IT injection of HGT-1110.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HGT-1110
Description: Participants will receive IT injection of HGT-1110.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HGT-1110
Description: Participants will receive IT injection of HGT-1110.
Study: NCT04609891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: 10×109/L\<PLT\<75×109/L, avatrombopag tablet 60 mg once a day for 5-10 days.
Study: NCT02514798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Inductance Plethysmography (RIP) system
Description: Inspiratory tidal volume (VTi), respiratory rate (RR), breath duration (Ttot), inspiratory time (Ti) and fractional inspiratory time (Ti/Ttot) will be determined using a Respiratory Inductive Plethysmography (RIP) system. This will measure the thoracic and abdominal excursion of the subjects via two inductive wires which are sewn into the elastic bands that encircle the thorax and abdomen. The acquired signals represent changes in cross-sectional area and, following calibration to determine the relative contribution of each signal, and volume calibration using spirometry, their weighted sum will reflect VTi. The RIP companion software will be used to derive RR, Ttot, Ti and Ti/Ttot on a breath by breath basis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sentec transcutaneous monitoring system
Description: The oxygenation, the level of carbon dioxide, and the heart rate will be recorded using the Sentec transcutaneous monitoring system: a probe will be placed at the earlobe or on the forehead, and it will measure in a noninvasive way these parameters.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sentec transcutaneous monitoring system
Description: The oxygenation, the level of carbon dioxide, and the heart rate will be recorded using the Sentec transcutaneous monitoring system: a probe will be placed at the earlobe or on the forehead, and it will measure in a noninvasive way these parameters.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow humidified nasal oxygen delivery system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP (Positive Control)
Study: NCT01869205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial valve
Description: One-way endobronchial valves are placed in segmental bronchi of the most hyperinflated and least perfused lobe of the emphysematous lungs on computed tomography (CT). Before the procedure, we confirm that the target lobe has no collateral ventilation with other lobes using Chartis® System (Pulmonx, Inc. Redwood City, CA, USA).
Study: NCT03132935

Intervention type: PROCEDURE
Intervention: Telemedical support
Description: Telemedical support by a physician in a telemedicine centre
Study: NCT02237196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 157
Description: AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AMG 157
Description: AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.
Study: NCT05574660

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-Fat/High-Sugar (HF/HS) Diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-Fat/Low-Sugar (LF/LS) Diet
Study: NCT03786029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Patients will receive 320mg (10ml) Acetaminophen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale.
Study: NCT02237196

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cat Immunotherapy
Description: A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection
Study: NCT03786029

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 10ml Strawberry Juice (placebo), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Patients will receive 200mg (10ml) of Ibuprofen (Strawberry flavour), wait for 30 minutes after the administration, then they will be given the local anesthesia injection. Then the child will be asked to point to the face that fits the degree of pain on the self-reporting pain scale WBFS immediately after the injection.~The tooth will be extracted 10 minutes after the injection, then the child will be asked to record the degree of pain on the same scale immediately after the extraction.~Pain will be re-evaluated 15 minutes after the extraction.~The scale will be given to the parents in order to evaluate the post-extraction pain in 1 to 6 hours while the child is at home.~Parents' satisfaction will be evaluated using Likert fifth scale.
Study: NCT02237196

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat Immunotherapy
Description: A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat Immunotherapy Placebo
Description: Placebo for allergen-specific immunotherapy administered subcutaneously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cat Immunotherapy Placebo
Description: Placebo for allergen-specific immunotherapy administered subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMG 157 Placebo
Description: Placebo for AMG 157 administered intravenously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AMG 157 Placebo
Description: Placebo for AMG 157 administered intravenously
Study: NCT03892395

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: B-vitamin supplementation on bone health
Description: An intervention study to investigate the effect of B-vitamin supplementation for 2-years on bone health

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group; Vitamin D, a daily capsule containing 10 µg/day vitamin D
Description: Vitamin D, a daily capsule containing 10 µg/day vitamin D
Study: NCT01014364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: 50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
Study: NCT02367027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Single dose of 10 mg oral suspension (dry powder) in fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Single dose of 20 mg oral suspension (dry powder) in fed conditions.
Study: NCT02248753

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological cardioversion - Flecainide
Study: NCT02367027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Single dose of 10 mg oral suspension in fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Single dose of 10 mg tablet in fasted conditions.
Study: NCT01308827

Intervention type: PROCEDURE
Intervention: Blood culture
Description: A baseline blood culture will be obtained in all participants

Intervention type: PROCEDURE
Intervention: Other cultures per Clinical routine practice
Description: Cultures from other sterile sites will be obtained per routine clinical practice
Study: NCT01811810

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation therapy (XRT)

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation therapy (XRT)

Intervention type: OTHER
Group type: OTHER
Intervention: Androgen Deprivation Therapy (ADT)

Intervention type: OTHER
Group type: OTHER
Intervention: Androgen Deprivation Therapy (ADT)

Intervention type: OTHER
Group type: OTHER
Intervention: Chemotherapy
Study: NCT02248753

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical cardioversion
Study: NCT02580409

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise Intervention
Description: Investigators are proposing an innovative rehabilitative care program for older primary care patients at risk for mobility decline. The program targets newly identified risk factors for mobility decline and utilizes mobile health technology to deliver patient centered care more efficiently. Study participants will receive exercise instruction with a licensed physical therapist for an average of 8-10 training sessions, with the possibility of up to 16 sessions. some at home and some in the clinic. The exercise training sessions will focus on improving mobility, balance and ability to get up from a chair with the use of an exercise application (Wellpepper) being used on a study issued iPad.